Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Zapping the brain to calm dementia agitation

NCT ID NCT03846492

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores how non-invasive brain stimulation can help understand and treat agitation in people with Alzheimer's and mixed dementia. Researchers will use transcranial magnetic stimulation (TMS) and electroencephalography (EEG) to study brain activity, and test whether transcranial direct current stimulation (tDCS) can reduce agitation. The study involves 90 participants, including those with and without agitation, plus healthy volunteers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS)
What this could lead to
If successful, this could point toward a safe, non-drug treatment for agitation in dementia, improving quality of life for patients and caregivers.
What could go wrong
This is an early-stage study focused on understanding brain mechanisms, not a proven treatment. The sample is small (90 people), and results may not apply to all dementia patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants with AD+Agitation Inclusion: 1. Age 50 years or older. 2. Participant or substitute decision maker able and willing to provide informed consent. 3. Dementia due to probable or possible AD as defined by NIA-AA criteria. 4. Presence of mild to moderate agitation and/or aggression as defined by: Agitation in cognitive disorders. International Psychogeriatric Association Provisional Consensus Clinical and Research Definition. 5. Availability of a support person to accompany the participant to study appointments and provide collateral information as needed. 6. If taking medication for neuropsychiatric symptoms, the dose should be stable for at least 1 week. Exclusion: 1. Psychiatric diagnosis other than dementia significantly impacting the presentation. 2. Presence of delirium or other acute medical condition significantly contributing to agitation/aggression or making the study participation unsafe for a participant. 3. Any contraindication to TMS or tDCS. 4. Any other condition that in the opinion of principal investigator will make the study participation unsafe or non-feasible for the participant. 5. Currently taking anticonvulsants or benzodiazepines at a dose sufficient to cause interference with TMS-EEG. Participants with AD without aggression All the above inclusion/exclusion criteria except meeting the inclusion criterion 4 pertaining to agitation/aggression. Participants with significant agitation/aggression will be excluded from this group. Healthy comparator participants Inclusion: 1. Age 50 years or older. 2. Able and willing to provide informed consent. 3. Free from any significant neurological disorder. Exclusion: 1. Lifetime DSM-5 diagnosis other than simple phobias or adjustment disorder. 2. Any Contraindication to TMS. 3. Currently taking anticonvulsants or benzodiazepines at a dose sufficient to cause interference with TMS-EEG.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Aberrant Motor Behavior in Dementia Alzheimer disease dementia Mixed Dementias psychiatric disorder Psychomotor Agitation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for Addiction and Mental Health

    Toronto, Ontario, M6J 1H4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.